Psychopharmacological Drugs Advisory Committee
February 14, 2001
NDA 21-253: Zyprexa® (olanzapine IM, Eli Lilly, Inc.)
Eli Lilly and Company
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Food and Drug Administration
Review and Evaluation of Clinical Data
Statistical Review and Evaluation